701-1444

completed

Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
701 (USA) · Dr. Reyes
consented 2013-01-05

AEs

Serious

Dropout signal

–

Adverse events

mild assessed

Mild APPLICATION SITE ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-01-19 (study day 15.0); relationship: POSSIBLE

moderate assessed

Moderate APPLICATION SITE ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-01-19 (study day 15.0); relationship: POSSIBLE

moderate assessed

Moderate APPLICATION SITE IRRITATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-02-04 (study day 31.0); relationship: PROBABLE

mild assessed

Mild APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-01-19 (study day 15.0); relationship: PROBABLE

moderate assessed

Moderate APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-01-19 (study day 15.0); relationship: PROBABLE

moderate assessed

Moderate APPLICATION SITE VESICLES — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-02-04 (study day 31.0); relationship: PROBABLE

mild assessed

Mild PARAESTHESIA — outcome: RECOVERED/RESOLVED; onset 2013-02-08 (study day 35.0); relationship: NONE

mild assessed

Mild SALIVARY HYPERSECRETION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-01-19 (study day 15.0); relationship: POSSIBLE

Data queries

No data queries.